These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 20586990)

  • 61. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.
    Padula WV; Larson RA; Dusetzina SB; Apperley JF; Hehlmann R; Baccarani M; Eigendorff E; Guilhot J; Guilhot F; Hehlmann R; Mahon FX; Martinelli G; Mayer J; Müller MC; Niederwieser D; Saussele S; Schiffer CA; Silver RT; Simonsson B; Conti RM
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26944912
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.
    Darkow T; Henk HJ; Thomas SK; Feng W; Baladi JF; Goldberg GA; Hatfield A; Cortes J
    Pharmacoeconomics; 2007; 25(6):481-96. PubMed ID: 17523753
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe--impact of cost considerations.
    Gratwohl A; Baldomero H; Schwendener A; Gratwohl M; Urbano-Ispizua A; Frauendorfer K
    Leukemia; 2007 Mar; 21(3):383-6. PubMed ID: 17311065
    [No Abstract]   [Full Text] [Related]  

  • 64. Imatinib for chronic myeloid leukaemia: a NICE mess.
    Barbour V
    Lancet; 2001 Nov; 358(9292):1478. PubMed ID: 11705557
    [No Abstract]   [Full Text] [Related]  

  • 65. Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib.
    Ohm L; Lundqvist A; Dickman P; Höglund M; Persson U; Stenke L; Carlsson KS; Björkholm M
    Leuk Lymphoma; 2015 May; 56(5):1385-91. PubMed ID: 25139694
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Assessment of Dasatinib Versus Nilotinib as Upfront Therapy for Chronic Phase of Chronic Myeloid Leukemia in Qatar: A Cost-Effectiveness Analysis.
    Adel A; Abushanab D; Hamad A; Abdulla M; Izham M; Yassin M
    Cancer Control; 2021; 28():10732748211001796. PubMed ID: 33887995
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Imatinib for chronic myeloid leukaemia: a NICE mess.
    O'Brien SG
    Lancet; 2001 Dec; 358(9296):1902-3. PubMed ID: 11741654
    [No Abstract]   [Full Text] [Related]  

  • 68. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients.
    Wu EQ; Johnson S; Beaulieu N; Arana M; Bollu V; Guo A; Coombs J; Feng W; Cortes J
    Curr Med Res Opin; 2010 Jan; 26(1):61-9. PubMed ID: 19905880
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Economic Evaluations of Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia in Middle- and High-Income Countries: A Systematic Review.
    Fu J; Liu Y; Lin H; Wu B
    Clin Drug Investig; 2018 Dec; 38(12):1167-1178. PubMed ID: 30232698
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia.
    Kattan MW; Inoue Y; Giles FJ; Talpaz M; Ozer H; Guilhot F; Zuffa E; Huber SL; Beck JR
    Ann Intern Med; 1996 Oct; 125(7):541-8. PubMed ID: 8815752
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group.
    Efficace F; Breccia M; Saussele S; Kossak-Roth U; Cardoni A; Caocci G; Chie W; Naeem A; Nicolatou-Galitis O; Cocks K; Vignetti M; Baccarani M; Mandelli F; Sprangers M
    Ann Hematol; 2012 Sep; 91(9):1371-81. PubMed ID: 22543826
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cost-effectiveness analysis of dasatinib versus imatinib in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia patients in China.
    Cao W; Yu Y; Qiu Y; Liu L; Zhang H; Shi L; Xiao Y; Jia L; Zhang R; Wang X
    BMC Health Serv Res; 2022 Dec; 22(1):1580. PubMed ID: 36567324
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Do affluent societies have the only options for the best therapy?
    Gajewski JL; Robinson P
    Leukemia; 2007 Mar; 21(3):387-8. PubMed ID: 17311066
    [No Abstract]   [Full Text] [Related]  

  • 74. Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia.
    Kim K; McMillin GA; Bernard PS; Tantravahi S; Walker BS; Schmidt RL
    PLoS One; 2019; 14(12):e0226552. PubMed ID: 31869360
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Increasing access to care for chronic myeloid leukemia patients: assessment of a scaling-up program.
    Ladner J; Tekinturhan E; Tavolacci MP; Audureau E; Saba J
    J Health Care Poor Underserved; 2013 Nov; 24(4):1486-97. PubMed ID: 24185146
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Linking Costs and Survival in the Treatment of Older Adults With Chronic Myeloid Leukemia: An Analysis of SEER-Medicare Data From 1995 to 2007.
    Lin PJ; Winn AN; Parsons SK; Neumann PJ; Weiss ES; Cohen JT
    Med Care; 2016 Apr; 54(4):380-5. PubMed ID: 26759984
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Indian patients go to court over cancer drug.
    Murdur G
    BMJ; 2004 Aug; 329(7463):419. PubMed ID: 15321889
    [No Abstract]   [Full Text] [Related]  

  • 78. Enabling access to molecular monitoring for chronic myeloid leukemia patients is cost effective in China.
    Maheshwari VK; Slader C; Dani N; Gkitzia C; Yuan Q; Xiong T; Liu Y; Viana R
    PLoS One; 2021; 16(10):e0259076. PubMed ID: 34695169
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cost-effectiveness of interferon alfa in chronic myelogenous leukemia.
    Liberato NL; Quaglini S; Barosi G
    J Clin Oncol; 1997 Jul; 15(7):2673-82. PubMed ID: 9215840
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia.
    Reed SD; Anstrom KJ; Li Y; Schulman KA
    Pharmacoeconomics; 2008; 26(5):435-46. PubMed ID: 18429659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.